Clinical Study
Helical Tomotherapy for Inoperable Breast Cancer: A New Promising Tool
Table 1
Patient and tumor characteristics.
| | Characteristic | Value |
| Age
Median (range) | 62 (28–65) | | Clinical Stage* | | | IIB | 1 | | IIIA | 1 | | IIIB-IIIC | 3 | Tumor diameter in mm
Median (range) | 88 (75–160) | | Laterality | | | Right sided | 3 | | Left sided | 2 | | Hormonal receptors and HER2 over-expression | | | ER−, PR−, HER2− | 2 | | ER+, PR−, HER2− | 1 | | ER+, PR+, HER2− | 1 | | ER−, PR−, HER2+ | 1 | | Histological grade | | | 2 | 1 | | 3 | 4 | | Number of mitoses/10 high power field | | | <11 | 1 | | >22 | 4 | | Initial chemotherapy regimen before HT | | | EC + docetaxel | 3 | | FEC + docetaxel | 1 | | Docetaxel + trastuzumab | 1 | | Adjuvant hormonotherapy | | | Yes | 2 | | No | 3 |
|
|
Abbreviations: ER: oestrogen receptor, PR: progesterone receptor, HER2: Human Epidermal Growth Factor Receptor 2, *AJCC Cancer Staging Manual, Seventh Edition (2010), EC: epirubicin, cyclophosphamide, FEC: 5fluorouracil, epirubicin, cyclophosphamide, Elston-Ellis modification of Scarff-Bloom-Richardson grading system.
|
